PMID: 9421122Jan 8, 1998Paper

Combination treatment with ranitidine is highly efficient against Helicobacter pylori despite negative impact of macrolide resistance

Helicobacter
K HulténL Engstrand

Abstract

This double-blind, randomized study evaluated the efficacy of dual and triple therapies including ranitidine for treatment of Helicobacter pylori infection. Dyspeptic patients (n = 105) with a positive rapid urease test formed the intention-to-treat population (ITT). All patients were assigned to 14 days treatment with ranitidine 300 mg b.i.d and clarithromycin 750 mg b.i.d. Group A (n = 53) also received a placebo twice daily, while group B (n = 52) received lymecycline 300 mg b.i.d. Treatment with ranitidine, 150 mg b.i.d, was continued for an additional 30 days. H. pylori infection was verified by culture. Twelve weeks after antibiotic treatment, H. pylori status was investigated by culture and 14C-urea breath test (UBT). The per-protocol (PP) group consisted of 73 patients (A, n = 38; B, n = 35). Cure rates were 87% (95% C.I. = 72% to 94%) vs. 72% (95% C.I. = 58% to 83%) in the ITT-group and 89% (95% C.I. = 73% to 97%) vs. 87% (95% C.I. = 72% to 96%) in the PP-population (culture and UBT) when triple and dual therapies were compared. In all patients who were not cured, clarithromycin resistance of H. pylori was acquired. Side effects were experienced by 54% of patients. The difference in efficacy between the two treatment r...Continue Reading

References

Jan 1, 1992·Antimicrobial Agents and Chemotherapy·H RautelinT U Kosunen
Jan 1, 1991·International Urology and Nephrology·J PeiserY Hertzanu
Apr 1, 1989·Pharmacology & Toxicology·J E KristiansenL P Andersen
May 1, 1995·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M NakaoM Uekata
Mar 1, 1995·Antimicrobial Agents and Chemotherapy·K V Clemons, D A Stevens
Apr 1, 1994·Current Opinion in Immunology·E J Jenkinson, G Anderson
Jan 1, 1995·Scandinavian Journal of Gastroenterology. Supplement·J M GötzC B Lamers
Feb 1, 1996·Antimicrobial Agents and Chemotherapy·J VersalovicM F Go
Dec 1, 1996·European Journal of Gastroenterology & Hepatology·I M DrakeA H Clarke
Nov 1, 1996·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A A van ZwetJ C Thijs

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Related Papers

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
T AlarcónM López-Brea
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
T AlarcónM López-Brea
© 2021 Meta ULC. All rights reserved